Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00283582 · ClinicalTrials.gov registry record · Phase 3

Trial of Primary Prophylaxis With rhTPO Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy

A Phase 3 study, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 3
Development phase
50
Enrollment target

NCT00283582: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.

NCT00283582 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 50 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00283582, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 3
Development phase
50 participants
Enrollment target

Study Summary

Intensive chemotherapy is often associated with low platelet counts often requiring platelet transfusions to maintain platelet counts. In previous clinical studies administration of rhTPO has been demonstrated to increase platelet counts.

Interventions

  • DRUG rhTPO

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2001-06
Est. Completion 2004-11
Phase Phase 3
M.D. Anderson Cancer Center

2,692 total trials

What the finished NCT00283582 record still lists

NCT00283582 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower).

The record links to 0 conditions, and to 1 intervention - of which rhTPO is the first listed.

NCT00283582 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00283582 about?

NCT00283582 is a clinical study titled "Trial of Primary Prophylaxis With rhTPO Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy". Intensive chemotherapy is often associated with low platelet counts often requiring platelet transfusions to maintain platelet counts. In previous clinical studies administration of rhTPO has been demonstrated to increase platelet counts.

What is the current status of trial NCT00283582?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2001-06. Estimated completion is 2004-11.

What interventions are being tested in trial NCT00283582?

The interventions under investigation include: rhTPO (DRUG).

Who is sponsoring clinical trial NCT00283582?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00283582's enrollment target sits among peer trials

50 1844th of 2000 higher than 141 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00283582, the US trial registry maintained by the National Library of Medicine. NCT00283582 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.